Sponsored
Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.
Feature|Videos|July 16, 2025
Enhancing CDMO Capabilities to Meet Evolving Client Needs
Author(s)Benedikt von Braunmühl, Rentschler Biopharma
Rentschler Biopharma is evolving its CDMO capabilities through strategic partnerships, infrastructure investments, and sustainability initiatives to better support clients' complex biologics programs.
Contract development and manufacturing organizations (CDMOs) play an increasingly vital role in the biopharmaceutical industry—evolving from simple capacity providers to strategic, integrated partners. As biopharma pipelines grow more complex and patient needs become more individualized, CDMOs like Rentschler Biopharma are continuously innovating to support clients in bringing life-changing therapies to market quickly, safely, and sustainably.
Watch this video and learn more about:
- How CDMOs are shifting from service providers to strategic partners with deep expertise and integrated support for complex programs.
- Investing in infrastructure to achieve scalability and how targeted expansions help meet client needs from clinical to commercial production.
- Ways in which environmental initiatives create added value for clients and patients in addition to improved sustainability.
Related to this article